Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Room B3 C346A, 10 Center Drive , Bethesda , Maryland 20892 , United States.
ACS Chem Neurosci. 2018 Nov 21;9(11):2620-2627. doi: 10.1021/acschemneuro.8b00103. Epub 2018 Jun 13.
In our preceding paper (Part 1), we identified three 1,5-bis-diaryl-1,2,4-triazole-based compounds that merited evaluation as potential positron emission tomography (PET) radioligands for selectively imaging cyclooxygenase-1 (COX-1) in monkey and human brain, namely, 1,5-bis(4-methoxyphenyl)-3-(alkoxy)-1 H-1,2,4-triazoles bearing a 3-methoxy (PS1), a 3-(2,2,2-trifluoroethoxy) (PS13), or a 3-fluoromethoxy substituent (PS2). PS1 and PS13 were labeled from phenol precursors by O-C-methylation with [C]iodomethane and PS2 by O-F-fluoroalkylation with [H,F]fluorobromomethane. Here, we evaluated these PET radioligands in monkey. All three radioligands gave moderately high uptake in brain, although [H,F]PS2 also showed undesirable radioactivity uptake in skull. [C]PS13 was selected for further evaluation, mainly based on more favorable brain kinetics than [C]PS1. Pharmacological preblock experiments showed that about 55% of the radioactivity uptake in brain was specifically bound to COX-1. An index of enzyme density, V, was well identified from serial brain scans and from the concentrations of parent radioligand in arterial plasma. In addition, V values were stable within 80 min, suggesting that brain uptake was not contaminated by radiometabolites. [C]PS13 successfully images and quantifies COX-1 in monkey brain, and merits further investigation for imaging COX-1 in monkey models of neuroinflammation and in healthy human subjects.
在我们之前的论文(第 1 部分)中,我们鉴定了三种基于 1,5-双二芳基-1,2,4-三唑的化合物,它们值得作为潜在的正电子发射断层扫描(PET)放射性配体进行评估,用于选择性地在猴和人脑内成像环氧化酶-1(COX-1),即,具有 3-甲氧基(PS1)、3-(2,2,2-三氟乙氧基)(PS13)或 3-氟甲氧基取代基的 1,5-双(4-甲氧基苯基)-3-(烷氧基)-1H-1,2,4-三唑。PS1 和 PS13 是由酚前体通过 [C]碘甲烷的 O-C-甲基化标记的,PS2 是通过 [H,F]氟溴甲烷的 O-F-氟烷基化标记的。在此,我们在猴中评估了这些 PET 放射性配体。所有三种放射性配体在脑中的摄取均较高,尽管 [H,F]PS2 也在颅骨中显示出不理想的放射性摄取。[C]PS13 被选为进一步评估,主要是基于比 [C]PS1 更有利的脑动力学。药理学预阻断实验表明,脑内放射性摄取的约 55%是特异性结合到 COX-1。酶密度指数 V 可以从连续脑扫描和动脉血浆中放射性配体的浓度中很好地识别出来。此外,V 值在 80 分钟内保持稳定,表明脑摄取未受到放射性代谢物的污染。[C]PS13 成功地在猴脑中成像和定量 COX-1,并值得进一步研究用于在神经炎症的猴模型中和在健康人类受试者中成像 COX-1。